Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 29, 2016 07:30 ET | Source: KemPharm

KemPharm Receives Clearance from FDA to Initiate Clinical Program for KP201/IR, a Single-Entity Benzhydrocodone HCl Immediate Release Abuse-Deterrent Prodrug for the Treatment of Acute Pain

KP201/IR could be the first single entity (APAP-free), IR hydrocodone product for pain analgesia with abuse-deterrent properties CORALVILLE, Iowa, Nov. 29, 2016 (GLOBE NEWSWIRE) --...
November 09, 2016 16:10 ET | Source: KemPharm

KemPharm, Inc. Reports Third Quarter 2016 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 5:00 p.m., ET Recent Clinical Development & Regulatory Highlights: Prioritized KP415 and KP201/IR as...
November 03, 2016 07:30 ET | Source: KemPharm

KemPharm Appeals FDA Complete Response Letter on Apadaz™ by Initiating a Formal Dispute Resolution Process

CORALVILLE, Iowa, Nov. 03, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary...
November 01, 2016 07:30 ET | Source: KemPharm

KemPharm, Inc. to Report Third Quarter 2016 Results

Conference Call and Live Audio Webcast Scheduled for November 9th, 2016, 5:00 p.m. ET CORALVILLE, Iowa, Nov. 01, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty...
October 25, 2016 07:33 ET | Source: KemPharm

KemPharm Files IND for KP201/IR, a Single-Entity Benzhydrocodone HCl Immediate Release Abuse-Deterrent Prodrug for the Treatment of Acute Pain

KP201/IR could be the first single entity (APAP-free), IR hydrocodone product for pain analgesia with abuse-deterrent properties CORALVILLE, Iowa, Oct. 25, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc....
October 18, 2016 06:30 ET | Source: KemPharm; Acura Pharmaceuticals

KemPharm Announces Licensing Agreement with Acura Pharmaceuticals for Aversion® Abuse-Deterrent Technology

Agreement focused on KemPharm’s current and in-development IR Opioid Pipeline CORALVILLE, Iowa and PALATINE, Ill., Oct. 18, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage...
October 11, 2016 07:30 ET | Source: KemPharm

KemPharm Receives Clearance from FDA to Initiate Clinical Program for KP415, an Investigational Prodrug of D-Threo-Methylphenidate for the Treatment of ADHD

CORALVILLE, Iowa, Oct. 11, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary...
September 19, 2016 07:03 ET | Source: KemPharm

KemPharm Files IND for KP415 for the Treatment of ADHD, An Investigational Prodrug of D-Threo-Methylphenidate

CORALVILLE, Iowa, Sept. 19, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary...
September 15, 2016 07:00 ET | Source: KemPharm

KemPharm, Inc. Provides Corporate and Clinical Update

Conference Call and Live Audio Webcast Scheduled for Today at 8:30 a.m. ET KemPharm adjusts product development timelines following full pipeline analysis and positions KP415 and KP201/IR...
September 08, 2016 07:30 ET | Source: KemPharm

KemPharm to Present Data at PAINWeek 2016

CORALVILLE, Iowa, Sept. 08, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary...